Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsResearch Summary
Analyzed using Evidence Intelligence™
Suvorexant shows no efficacy for insomnia in type 2 diabetes
Last updated July 11, 2026
Key finding
There were no significant improvements in sTST (p = 0.27).
This study evaluated the efficacy of Suvorexant in improving sleep and health outcomes in individuals with Type 2 diabetes and insomnia, finding no significant improvements.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save this study and add notes to your research library.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the efficacy of Suvorexant in improving sleep and health outcomes in individuals with Type 2 diabetes and insomnia, finding no significant improvements.
Clinical relevance
Understanding the effectiveness of treatments for insomnia in individuals with Type 2 diabetes is crucial, as sleep disturbances can exacerbate health issues. This study's findings suggest that Suvorexant may not be a beneficial option for improving sleep or related health outcomes in this population, guiding clinicians in treatment decisions.
Keep in mind
Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Lack of significant findings raises questions about treatment efficacy.
Published in
Journal Reference
Publication details and source links for this paper.
John WW, Benjamin W, Jordana Z, Bettina BH. Efficacy of Suvorexant in Improving Sleep and Health Outcomes in People with Type 2 Diabetes and Insomnia. Nature and Science of Sleep. 2023;15:1117-1128. doi:10.2147/NSS.S434058
Main Effects
No significant improvements in subjective total sleep time (p = 0.27).
No significant changes in insomnia severity index scores (p = 0.86).
No significant improvements in wake time after sleep onset (p = 0.94).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Suvorexant and C-reactive protein, HbA1c, Reduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI), and 3 more.
This study contributes evidence to
Primary intervention
Suvorexant
Primary outcomes
- C-reactive protein
- HbA1c
- Reduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
6
Evidence pairs
211
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Track related evidence
Follow the evidence behind this paper in your workspace.
Primary evidence
Evidence topic
HbA1c Reduction
matched_outcome
Related evidence
Evidence topic
Inflammatory and Vascular Markers
Follow evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsReduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI)
Suvorexant → Reduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI)
Suvorexant → Reduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI)
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsTotal sleep time measured in minutes
Suvorexant → Total sleep time measured in minutes
Suvorexant → Total sleep time measured in minutes
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsWake time after sleep onset in minutes
Suvorexant → Wake time after sleep onset in minutes
Suvorexant → Wake time after sleep onset in minutes
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsUnlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Suvorexant showed no significant effect on sleep time or quality.
- Insomnia severity did not improve with Suvorexant (p = 0.86).
- Health markers like HbA1c and CRP remained unchanged.
Who this applies to
- Adults with Type 2 diabetes.
- Individuals experiencing insomnia.
Keep in Mind
- Results may not apply to populations outside the study sample.
- Further research is needed to explore other treatment options.
- Findings do not support the use of Suvorexant for this condition.
Between the Lines
- Limited sample size may affect generalizability.
- Short duration of the study may not capture long-term effects.
- Lack of significant findings raises questions about treatment efficacy.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Suvorexant and Inflammatory Markers, Suvorexant and HbA1c.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceSuvorexant → Inflammatory Markers
Medications
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceSuvorexant → HbA1c
Medications
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
1 studies
outcome_hubMeasures HbA1c as a key outcome.
Inflammatory Markers Evidence Hub
All studies measuring Inflammatory Markers
1 studies
outcome_hubMeasures Inflammatory Markers as a key outcome.
Suvorexant Evidence Hub
All studies on Suvorexant
1 studies
intervention_hubContributes to Suvorexant evidence base.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Suvorexant and C-reactive protein
Intervention: SuvorexantOutcome: C-reactive protein
1 results
All studies on Suvorexant and HbA1c
Intervention: SuvorexantOutcome: HbA1c
1 results
All studies on Suvorexant
Intervention: Suvorexant
1 results
All studies measuring C-reactive protein
Outcome: C-reactive protein
1 results
All studies measuring HbA1c
Outcome: HbA1c
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Suvorexant improve c-reactive protein?
Emerging Evidence
Current evidence does not show a clear benefit of Suvorexant for C-reactive protein.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-reactive protein
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Suvorexant improve HbA1c?
Emerging Evidence
Current evidence does not show a clear benefit of Suvorexant for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Suvorexant improve reduction in insomnia symptoms measured by insomnia severity index (isi)?
Emerging Evidence
Current evidence does not show a clear benefit of Suvorexant for Reduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Reduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Suvorexant improve sleep efficiency?
Emerging Evidence
Current evidence does not show a clear benefit of Suvorexant for Sleep efficiency.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Sleep efficiency
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Exercise Improves Sleep Quality in Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesNatural products may improve glycemic control in type 2 diabetesNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetesAID improves glycaemia but worsens sleep in young T1D patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.